Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) will likely be issuing its results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.53. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Price Performance

NASDAQ:ALZN opened at $1.98 on Friday. Alzamend Neuro has a one year low of $1.58 and a one year high of $10.17. The company has a fifty day moving average price of $2.06 and a 200 day moving average price of $2.23. The stock has a market cap of $7.52 million, a P/E ratio of -0.60 and a beta of -0.25.

Hedge Funds Weigh In On Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC boosted its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,506 shares of the company’s stock after buying an additional 6,928 shares during the quarter. Geode Capital Management LLC owned approximately 0.72% of Alzamend Neuro worth $50,000 at the end of the most recent quarter. 49.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ALZN has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Alzamend Neuro in a report on Monday, December 29th. Ascendiant Capital Markets lowered their price target on Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.